Top Markets
Coin of the day
Homology Medicines, Inc. Homology Medicines, Inc.

Homology Medicines, Inc.

FIXX
Rank in Stocks #39911
Homology Medicines, Inc. is a biotechnology firm dedicated to genetic... Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissuesโ€”such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyesโ€”all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.
Share Price
$0.9347
Last synced: 2024-03-25
Market Cap
$300.42K
Change (1 day)
0.75%
Change (1 year)
0.00%
Country
US
Trade Homology Medicines, Inc. (FIXX)

Category

P/S ratio for Homology Medicines, Inc. (FIXX)
P/S ratio as of 2026 TTM: 0
According to Homology Medicines, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Homology Medicines, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE